EAM
VRNA

Eventide Asset Management’s Verona Pharma VRNA Stock Holding History

Eventide Asset Management’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-680,929
Closed -$72.7M – 288
2025
Q3 		$72.7M Sell
680,929
-2,034,395
-75% -$212M 1.19% 20
2025
Q2 		$257M Sell
2,715,324
-178,113
-6% -$13.2M 4.5% 1
2025
Q1 		$184M Sell
2,893,437
-238,690
-8% -$14.3M 3.66% 1
2024
Q4 		$145M Buy
3,132,127
+706,281
+29% +$26.5M 2.65% 1
2024
Q3 		$69.8M Buy
2,425,846
+1,898,065
+360% +$46.7M 1.2% 25
2024
Q2 		$7.63M Sell
527,781
-1,659,739
-76% -$24.2M 0.13% 131
2024
Q1 		$35.2M Buy
2,187,520
+809,739
+59% +$14M 0.55% 64
2023
Q4 		$27.4M Buy
1,377,781
+527,781
+62% +$7.79M 0.45% 68
2023
Q3 		$13.9M Buy
+850,000
New +$16.4M 0.25% 106

Other funds holding VRNA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Eventide Asset Management's VRNA Position: Q4 2025 in Review

Eventide Asset Management sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 680,929 shares — an estimated $72.7M sold.

Eventide Asset Management first reported a position in VRNA in Q3 2023 and held it in 9 quarters. The position peaked at $257M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

  • Eventide Asset Management reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
  • Eventide Asset Management sold 680,929 Verona Pharma shares in Q4 2025, an estimated $72.7M.
  • Eventide Asset Management first reported a position in Verona Pharma in Q3 2023 and held it in 9 quarters.
  • Eventide Asset Management's Verona Pharma position peaked at $257M in Q2 2025.
  • 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Eventide Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.